Igc reports qtrly loss per share of $0.05

Igc reports financial results for the quarter ended june 30, 2020 while preparing for its fda-approved cannabinoid clinical trials on alzheimer’s patients.quarterly loss per share $0.05.
IGC Ratings Summary
IGC Quant Ranking